1. Introduction {#sec1}
===============

The speed in which new medical analytical techniques have been developed during the past century has been monumental. "Omics", a group of biological fields comprising genomics, transcriptomics, proteomics, and metabolomics allow for high-throughput, simultaneous analysis of vast numbers of molecules within a biological sample \[[@B1]--[@B6]\]. The last of these, metabolomics, is defined as the study of metabolites, a recognized field of study arising in the 1960s aimed at developing a better understanding of cellular biology \[[@B7]--[@B9]\]. However, its nomenclature is relatively new; the term "metabolomics" was coined in the early 2000s \[[@B10]\]. The study of metabolomics facilitates an increased understanding of all the endogenous and exogenous low-molecular weight molecules (\<1500 Da) which are downstream products from interactions on a genomic or proteomic level \[[@B11]--[@B13]\].

Within metabolomics, the study of the "exposome", defined as an individual\'s total exogenous footprint derived from exogenous factors that exert a significant influence on an individual\'s biochemistry, is a relatively new but quickly popularizing discipline for biomarker screening \[[@B14], [@B15]\]. The total metabolic profile therefore reflects the biochemical changes of a living cell or organism brought about by certain physiological conditions or in response to an external environmental stimulus. This provides insight into the underlying mechanism of disease development and progression and can act as the bridge between genetic factors and environmental exposures, revealing clues to the origin of the resultant phenotypes of different individuals \[[@B16]--[@B18]\].

Metabolomics has become a fast growing area of interest for research into the prognosis, screening, diagnosis, and treatment of many diseases \[[@B19]--[@B23]\]. Medical metabolomics research has been focused on the identification and investigation of relevant metabolites formed during certain pathological metabolic reactions. The process begins with untargeted screening of the metabolome (the entire set of small molecules contained in a biological sample). Overall associations between metabolites with significantly altered levels from control are identified and analyzed to generate a hypothesis. A more targeted approach is then utilized, focusing on the metabolites with significantly altered values to further investigate the consistency of results and prove or disprove the proposed hypothesis. A variety of biological specimens, namely, serum, urine, tissue, cerebrospinal fluid, hair, saliva, stool, and exhaled breath, have been used in analysis to study human pathology \[[@B13], [@B24]--[@B26]\].

Mass spectrometry-based metabolomics has been utilized in studies of pregnancy complications such as preeclampsia (PE), fetal growth restriction (FGR), gestational diabetes mellitus (GDM), and preterm birth (PB). The biomarkers related to these complications are analyzed to obtain better knowledge concerning the underlying pathological changes at a cellular metabolic level. The end goal is to develop a more individualised method of screening and treatment plan for each patient according to their metabolic phenotype. However, a greater understanding of the pathophysiology of each condition is first required \[[@B27]\].

In initial metabolomic studies of pregnancy-related complications, urine and blood were used. However, the use of hair as a metabolomic sample has generated increasing interest due to its noninvasive nature and the stability of compounds residing in the hair matrix. Unlike urine and blood, results from a metabolomic investigation of hair do not fluctuate from hour to hour. The metabolomic study of human hair will allow for retrospective studies to be performed, by way of segmental analysis on a single strand of hair \[[@B28], [@B29]\]. Hence, metabolomic analysis of hair can provide a record of the chemical effects from long-term exposure of known teratogenic pollutants such as tobacco, alcohol, and drugs \[[@B30]--[@B32]\].

2. Metabolomics of Adverse Pregnancy Outcomes {#sec2}
=============================================

2.1. Preeclampsia {#sec2.1}
-----------------

Preeclampsia is prevalent in 3-8% of all pregnancies worldwide \[[@B33]\], with a high maternal mortality rate of \>50,000 per year \[[@B34]\]. It is defined by hypertension with a BP of over 140/90 mmHg measured at two consecutive times within a 6-hour period and proteinuria of \>300mg/day, in pregnant women with gestational ages beyond 20 weeks. The precise aetiology of preeclampsia remains unclear. However, it is generally accepted that the condition arises from defective vascularization of the placenta. Abnormal extravillous trophoblastic penetration into the muscular layer of spiral arteries in the uterus leads to reduced uteroplacental blood flow. Diminished placental blood perfusion will then give rise to ischaemia, oxidative stress, and inflammation. The two characteristic signs of preeclampsia, namely, proteinuria and hypertension due to endothelial injury, arise from the release of inflammatory cytokines released in the aforementioned process \[[@B33]\].

Preeclampsia can potentially progress to complications such as eclamptic seizures and hemolysis, elevated liver enzymes and lowered platelet count syndrome (HELLP syndrome), and acute complications such as renal or cardiac failure \[[@B33], [@B35], [@B36]\]. Long-term maternal implications include an increased risk of developing cardiovascular disease postpartum. Preeclampsia also influences fetal growth and development, often resulting in fetal growth restriction (FGR) and preterm birth (often iatrogenic) \[[@B37]\].

Previous metabolomics investigations are summarized in [Table 1](#tab1){ref-type="table"}, demonstrating the significantly altered values of certain metabolites in patients with preeclampsia as compared to healthy pregnancies. Lipid peroxidation and altered lipoprotein concentrations have been linked to endothelial dysfunction and oxidative stress, and indeed one of the notable findings consistent in several of these studies is the altered values of metabolites related to lipid metabolism. Carnitine, one of the metabolites related to transport of lipids from cytoplasm to mitochondria, has also been reported at significantly altered levels in preeclampsia ([Table 1](#tab1){ref-type="table"}). In addition, difference has been reported in levels of choline, an essential nutrient functioning in the metabolism of phospholipids; choline can also influence inflammation, apoptosis, and angiogenesis \[[@B38], [@B39]\]. Mukherjee et al. proposed an interesting hypothesis that change of fatty metabolism in the placenta associated with early-onset preeclampsia (\<34 weeks of gestation) can be reflected in maternal plasma metabolites \[[@B40]\]. Additionally, changes in the concentration of certain amino acids can be related to the risks for development of preeclampsia, such as a decrease in taurine, an amino acid released during trophoblast invasion into spiral arteries \[[@B41], [@B42]\].

2.2. Fetal Growth Restriction and Small for Gestational Age {#sec2.2}
-----------------------------------------------------------

A fetus is defined as small for its gestational age (SGA) when its estimated fetal weight falls below the 10th percentile \[[@B53], [@B54]\]. Evidence of SGA is not enough to determine a pathological diagnosis, as several other physiological factors such as maternal ethnicity and genetics can contribute to a low estimated fetal weight (EFW). A pathologic diagnosis of fetal growth restriction (FGR) (also known as intrauterine growth restriction, IUGR) is more likely when SGA is coupled with abnormal test results (such as an abnormal Uterine Artery Doppler) \[[@B53]\].

FGR can be attributed to several different factors, such as fetal genetic abnormalities and congenital infections (e.g., toxoplasmosis, malaria, and rubella). However, the majority of FGR is associated with some form of placental perfusion insufficiency \[[@B55]\]. Fetuses with FGR are at high risk of perinatal mortality and development of long-term morbidities such as neurodevelopmental delay, diabetes, and adult hypertension and diabetes \[[@B56], [@B57]\]. Current treatment plans include monitoring, administration of low-dose aspirin, and induction of preterm delivery \[[@B54]\].

Several metabolomic studies of SGA cases have shown significant alterations in relative concentration of certain metabolic classes between affected pregnancies as compared to uncomplicated pregnancies ([Table 2](#tab2){ref-type="table"}). For instance, Horgan et al. (2011) discovered a significant association between altered levels of sphingolipids and phospholipids in maternal blood and SGA \[[@B57]\]. Sphingolipids are a class of fatty acids that act as vital mediators in the cellular processes of apoptosis, proliferation, and stress responses \[[@B58], [@B59]\]. Therefore, they may be indicative aberrant cellular processes in cytotrophoblasts, resulting in placental insufficiency and FGR \[[@B60], [@B61]\]. Phospholipids are another class of fatty acids, comprising the major component of cell membranes. An increase in phospholipid levels in maternal serum is also indicative of cellular damage and apoptosis \[[@B62]\].

Van Vliet et al. (2013) studied metabolomic changes in fetal rabbit brain tissue when FGR was induced; 18 metabolites belonging to certain classes (neurotransmitters, amino acids and fatty acids related to energy metabolism, and oxidative stress) were found to have significantly altered values (p\< 0.05) \[[@B56]\]. Of particular note are the significantly decreased values of N-acetylaspartylglutamic acid (NAAG) and N-acetylaspartate (NAA), two cerebral-specific metabolites that are indicative of neuronal density and viability, providing insight to the correlation between FGR and fetal neurodevelopmental delay \[[@B63]\]. Vab Vliet et al. also identified a significant reduction of certain amino acid concentrations (asparagine, ornithine, histidine, and l-lysine) and pyroglutamic acid (precursor to glutamate) in fetal rabbit brain with induced FGR \[[@B56]\]. As amino acids and glutamate are important for brain growth, metabolism, and function, these findings are hardly unexpected. However, Favretto et al. (2014) have conversely discovered significantly increased levels of 7 alpha amino acids (including phenylalanine and tryptophan) and glutamate itself in cord blood \[[@B64]\].

2.3. Preterm Birth {#sec2.3}
------------------

PB is defined as delivery before 37 weeks of gestation and affects up to 12-13% of pregnancies \[[@B66]\]. It can be further classified into three categories: spontaneous labor with intact membranes (SPB), preterm premature rupture of the membranes (PPROM), and medically induced preterm labor (IPB, including cesarean sections for maternal and fetal indications) \[[@B66]\]. Understanding of the etiological processes that lead to PB remains limited. However, most SPB cases result from one or more of the following pathological processes: amniochorionic decidual or systemic inflammation, activation of the maternal/fetal hypothalamic--pituitary--adrenal, decidual haemorrhage, or pathological distension of the uterus. Cervicovaginal secretions or fluid could be collected easily in a noninvasive and repetitive way, at different times of gestation and parturition. In many cases, abnormal cervical structure, local inflammation, and high cervicovaginal fluid acetate integral of women appear as major precipitating factors of SPB \[[@B67], [@B68]\].

Although limited metabolomics study has been performed on PB, Maitre and Oladipo noted a heightened concentration of lysine (an essential amino acid) in maternal urine and premature neonatal plasma, respectively ([Table 3](#tab3){ref-type="table"}) \[[@B55], [@B69]\]. Maitre et al. (2014) have also noted an elevated lysine and steroid conjugate levels and significantly decreased levels of formate in urine samples related to spontaneous preterm birth (SPB). They speculated that an increase in N-acetylglycoprotein fragment in these urine samples was proportionately linked to higher risk of medically induced preterm birth (IPB) \[[@B55]\]. Since N-acetylglycoproteins are known to be inflammation-induced acute phase proteins in serum, this is not an unexpected finding \[[@B70]\]. However, it shows promising potential for early diagnosis of IPB indications.

2.4. Gestational Diabetes Mellitus {#sec2.4}
----------------------------------

Gestational diabetes (GDM) is currently defined as any degree of glucose intolerance with onset or first recognition during pregnancy \[[@B71]\]. The diagnostic criteria vary, but are based on fasting plasma glucose values and glucose value after a glucose load, typically tested at weeks 24-28 of pregnancy \[[@B72], [@B73]\]. GDM has an incidence of up to 15-20%, according to availability of sophisticated screening methods, population demographics, and criteria for diagnosis \[[@B71], [@B72]\]. Risk factors that have been correlated with GDM include advanced maternal age, race/ethnicity, obesity, and family history of type 2 diabetes mellitus (T2DM) \[[@B72]\].

As shown in [Table 4](#tab4){ref-type="table"}, several metabolites, such as those of lipids, glycerophospholipid, and carnitines, have been noted across various studies of GDM \[[@B74]--[@B76]\]. Another class of these metabolites is the branched-chain amino acids (BCAA). BCAAs have proven involvement in insulin resistance and suppression of insulin secretion, by impacting the mitochondria in pancreatic beta cells, and show an association with higher risk of developing GDM \[[@B77]--[@B80]\]. Several fatty acids and downstream products of fatty acid metabolism (which are associated with insulin resistance and glucose metabolism) have also shown downregulation in serum from maternal hyperglycemia and GDM cases \[[@B81]--[@B83]\]. Dudzik et al. (2014) discovered several significant differences in relative metabolite concentrations in the plasma and urine samples between hyperglycemic and healthy pregnant women. One of these was a significant decrease in glycerophospholipid levels, which could be attributed to change in glucose metabolism due to beta-cell dysfunction in cases of glucose intolerance \[[@B76]\].

Long-term effects on the mother include postpartum T2DM and cardiovascular disease \[[@B71], [@B72]\]. Furthermore, infants born to women with GDM are at increased risk for respiratory distress syndrome, macrosomia, jaundice, and obesity or other metabolic syndromes in later life \[[@B84], [@B85]\]. When diagnosed early, these adverse short-term and long-term health issues may be reduced through lifestyle intervention \[[@B71]\]. Therefore, the study and discovery of potential biomarkers for GDM are significant not only for its benefits for diagnosis and treatment of GDM itself, but also for prevention of further morbidities associated with T2DM.

3. Hair Metabolomics {#sec3}
====================

3.1. General Use of Hair in Clinical Applications {#sec3.1}
-------------------------------------------------

The use of hair as a biological specimen is commonplace in the measurement of toxic exposures. It began with accurate estimation of exposure to heavy metals and alcohol in the 1960s. Hair specimen have been used to determine the level of exposure to smoking, pesticides and drugs \[[@B7], [@B90], [@B91]\]. All of these substances lead directly or indirectly to adverse pregnancy outcomes \[[@B92]--[@B99]\]. Chemical markers detected in human hair specimens have proven to be both objective and accurate in the measurement of environmental exposure. One advantage of using hair as a biological sample is that it provides a broader view of an individual\'s metabolic profile. Both endogenous compounds and environmental chemicals are assimilated into hair during growth. Therefore, hair provides a metabolite profile that reflects the long-term effect of environmental exposure on pregnancy outcomes. In contrast, the more conventional samples such as blood and urine only provide transient biochemical profiles.

In addition, hair is a stable biological sample and can be stored for longer periods of time; no special preparations need to be conducted to prevent sample degradation, thus simplifying transport between laboratories.

There are, however, several limitations related to the use of hair in metabolomic studies. Lower concentrations of toxic substances are incorporated into hair as compared to those that can be analyzed in blood and urine samples. Therefore, instruments with higher sensitivity are required \[[@B100], [@B101]\]. Furthermore, gender, nutrition, melanin content of hair, lipophilicity, pH of molecules, agricultural exposures, and external contamination (through sweat or sebum) may all affect the incorporation of trace elements into hair \[[@B102]--[@B105]\]. Certain hair treatments, even as simple as shampoo, also affect the concentration of analytes found in hair.

### 3.1.1. Trace Element Exposure {#sec3.1.1}

Humans are commonly exposed to a variety of toxic trace elements. Arsenic, cadmium, lead, and mercury are known teratogenic factors and can contribute to neurotoxicity during pregnancy \[[@B97], [@B106]--[@B111]\]. While the more conventional samples such as urine and blood provide a more accurate measurement of physiological toxin concentrations, hair can be used to conduct a retrospective study that could provide more information of the times the toxin was ingested and the accumulation of toxins in the body over time.

Analytical methods have been dramatically improved in recent decades and hybrid generation-atomic fluorescence spectrometry \[[@B112], [@B113]\], inductively coupled plasma-mass spectrometry (ICP-MS) \[[@B102], [@B114]\], and atomic absorption spectrometry \[[@B103], [@B115], [@B116]\] are utilized to analyze trace elements in hair samples. A more simplistic method for ICP-MS was further developed to cut down on time and resources by coupling high-performance liquid chromatography with ICP-MS \[[@B117]\]. Another method, laser ablation-ICP-MS, gives the spatial distribution of trace elements in a single strand, thereby giving a timeline for exposure with a high degree of accuracy from a minute specimen \[[@B118]--[@B120]\].

### 3.1.2. Drug Abuse Analysis {#sec3.1.2}

Measuring complex molecules such as drugs in hair has proved to be more challenging than analysis of trace elements. While trace elements remain unmodified, drugs can be catabolised and it is often the byproducts or downstream metabolites that are incorporated. Therefore, analyses of these compounds require more sophisticated analysis techniques such as GC-MS and LC-MS. Nevertheless, analysis of hair samples remains a method for determining the presence or absence of certain drugs and to obtain a better understanding of absorption and metabolism of different drugs \[[@B121]\].

There are several advantages to using hair samples in investigations of illicit drug exposure. Firstly, it can be collected in person, thus removing the possibility of substitution, which is a common problem in urine sampling \[[@B122]\]. Secondly, unlike the fast clearance rate of these compounds (e.g., heroin) in blood and urine, drugs, and their byproducts remain stable in hair \[[@B121], [@B123], [@B124]\]. Finally, segmental analysis of hair samples allows one sample to give a picture for months compared to multiple blood tests, which could be useful for a longitudinal monitor of drugs abstinence \[[@B125]\].

Exposures to certain illicit and pharmaceutical drug compounds such as ACE-inhibitors and heroin during pregnancy have been proven to exert a teratogenic effect, providing a further indication in pregnancy \[[@B126]--[@B128]\].

The usual limitations of metabolomics hair analysis should be kept in mind. Moreover, Mercolini L. et al. discovered potential bias from external contamination of hair, for example, that consumption of cannabis could only be confirmed when both THC (tetrahydrocannabinol) and its metabolite THC-COOH were detected in the hair samples \[[@B129]\].

### 3.1.3. Alcohol Consumption via Hair Analysis {#sec3.1.3}

During the last decade, monitoring of alcohol consumption has advanced with the discovery of two types of alcohol metabolite, ethyl glucuronide (EtG), and fatty acid ethyl esters (FAEEs) (ethyl myristate, ethyl palmitate, ethyl oleate, and ethyl stearate) in hair \[[@B130]--[@B132]\]. Sensitivity and specificity of GC-MS and LC-MS analysis for detection and measurement of these compounds in hair are excellent and are often utilized in traffic law enforcement and liver transplant allocation \[[@B133]--[@B136]\]. Originally, it was believed that FAEE or EtG in hair can only be used for identifying rather than quantifying alcohol consumption \[[@B137]\]. However, in 2016 the Society of Hair Testing published a consensus for workable cut-off values ([Table 5](#tab5){ref-type="table"}). Cut-off values for FAEEs are adjusted according to hair segment used, to account for possible external concentrations of FAEEs into hair from cosmetic treatments.

EtG is predominantly incorporated into hair matrix by sweat \[[@B138]\], while FAEE incorporation is by sebum \[[@B139]\]. Tsanaclis et al. (2009) and Crunelle et al. (2015) discovered that one of the drawbacks of using only EtG in hair for measurement of alcohol consumption is that normal hair hygiene practices (e.g., shampooing) and cosmetic treatments (dyeing and bleaching) greatly reduces the concentration of EtG in hair as it is a hydrophilic compound \[[@B140], [@B141]\]. However, EtG concentration in hair is not influenced by the use of alcohol-containing hair products or by the use of hair spray, wax, gel, oil, or grease \[[@B142]\]. In contrast, FAEE is virtually unaffected by shampoo washing or dyeing, but its concentration may be increased by ethanol-containing lotions and hairspray \[[@B142], [@B143]\]. All of these factors and more (such as the site of hair collection) must be considered when determining an individual\'s abstinence or alcohol dependence. EtG and FAEEs are used in combination to increase reliability of the results \[[@B144]\].

### 3.1.4. Evaluating Tobacco Smoke Exposure Via Hair Analysis {#sec3.1.4}

During the past century, a large number of studies have been conducted on the long-term and short-term teratogenic effects of cigarette smoke \[[@B90], [@B145]\]. Nicotine and its catabolite cotinine are used in tobacco smoke exposure measurement. However, due to the short half-life of nicotine and cotinine, analytical techniques using conventional samples such as blood \[[@B146]\] and urine \[[@B147]\] have yet been able to accurately quantify the harmful concentrations and level of risk in development of pregnancy complications for pregnant women and their fetuses \[[@B146], [@B147]\].

Analysis of nicotine and cotinine in hair has been heralded as a solution. Several analytical techniques, namely, GC \[[@B90]\], RPHPLC \[[@B148]\], GC-MS \[[@B145]\], and HPLC \[[@B149]\] have been used to identify smokers. Of particular interest is the GC-MS platform and its ability to evaluate levels of passive smoking by hair sample \[[@B150]\], as it is less prone to interference and a smaller sample size is needed for analysis (e.g., 5 mg of hair from one test subject) \[[@B150]\]. Exposure to polycyclic Aromatic Hydrocarbons (PAHs), another substance found in cigarette smoke and heavy industry, can also be quantified in hair through GC-MS \[[@B145]\].

### 3.1.5. Evaluating Pesticide Exposure via Hair Analysis {#sec3.1.5}

In recent decades, many pesticides have been outright banned or its use severely restricted in Europe and several other countries \[[@B151]\]. However, pesticide use is still widespread, despite well-known carcinogenic, mutagenic, and teratogenic effects \[[@B152]--[@B156]\].

Blood and urine are routinely used to assess pesticide intake. These compounds can be directly measured in blood while their catabolites can be analyzed in urine. In addition to providing a method for retrospective analysis of pollutant exposure, both the compound itself and its catabolites can be analyzed in a single hair sample. GC-MS \[[@B157]\] or GC-MS/MS \[[@B158]\] are validated methods but both require a precleanup procedure, either liquid-liquid extraction (LLE) or solid-phase extraction (SPE), to purify the analytes and enhance sensitivity. A study conducted by Duca et al. (2014) found that SPE gives a better recovery rate of the analytes compared to LLE and reduces the background noise of the analysis via detecting sixty-seven pesticides and metabolites from different chemical classes including organochlorines, organophosphates, carbamates, pyrethroids, ureas, azoles, phenylpyrazoles, and neonicotinoids. \[[@B159]\]. In 2012, Salquèbre et al. applied an improved clean-up procedure developed from SPE called Solid-phase microextraction (SPME) that in combination with gas chromatography tandem (triple quadrupole) mass spectrometry was able to analyze smaller sample amounts due to its higher sensitivity \[[@B100]\].

4. Hair Metabolome Related to Adverse Pregnancy Outcomes {#sec4}
========================================================

The application and advantages of hair as a biological specimen have previously been discussed in the context of biological screening and toxin exposure. The use of hair to investigate the metabolome of pregnant women and research adverse pregnancy outcomes holds great potential. The incidence of adverse pregnancy outcomes is influenced by environmental and physiological changes from preconception until delivery. Analysis of hair could provide a wide perspective of the whole process as both endogenous (metabolome) and exogenous compounds (exposome) are incorporated. However, thus far, this potential has not been fully realized. There have only been two studies investigating the hair metabolome in pregnant women who suffer from certain pregnancy-related complications. These studies were done by Sulek et al. and He et al. on FGR \[[@B160]\] and GDM \[[@B161]\], respectively ([Table 6](#tab6){ref-type="table"}).

In the FGR study, hair samples were taken from 83 women at 26-28 weeks of gestation. 41 of these women subsequently delivered SGA fetuses, and the 42 remaining women delivered fetuses of normal weight, serving as controls. GC-MS based metabolite profiling of the hair samples was used to discover significant variations in a range of metabolites between cases and controls including amino acids, amino acid derivatives, fatty acids, cofactors, and antioxidants. Based on these results, a biomarker model was capable of distinguishing pregnancies complicated by FGR from normal pregnancies, using five metabolites, with a receiver-operating curve of 0.99. The authors also reported increased levels of heptadecane in samples obtained from FGR pregnancies. Heptadecane is an exogenous alkane hydrocarbon incorporated into the metabolome through air pollution and/or food contamination and may represent an environmental trigger that leads to FGR. Furthermore, elevated levels of NADPH/NADP in combination with decreased levels of glutathione observed in the FGR cases suggest redox imbalance and placental oxidative stress that may be another precipitating factor of FGR \[[@B56], [@B160]\].

More recently, the GDM study conducted by He et al. (2015) studied hair metabolite profiles from 47 cases diagnosed with GDM as compared to 47 controls with no pregnancy complications, at around 24-28 weeks of gestation. The hair metabolome analysis of GDM identified a significantly elevated level of adipic acid, a compound that had been found at elevated levels in urine of subjects with Type II diabetes and associated with oxidative stress \[[@B161]--[@B164]\]. One limitation of this study, however, was that hair analysis was performed on the whole hair strand. Therefore, the results represent the metabolic profile of both preconception and early gestational periods \[[@B161]\].

Both studies thus show promising results that could advance the understanding and clinical approach to these pregnancy complications.

5. Relating the Exposome to Adverse Pregnancy Outcomes {#sec5}
======================================================

The term "exposome" was first defined by Christopher Wild in 2005 and then underwent several modifications as the understanding of it developed over time \[[@B165]\]. The latest definition of the exposome, suggested by Miller and Jones, is "the cumulative measure of environmental influences and associated biological responses throughout the lifespan including exposures from the environment, diet, behaviour, and endogenous processes" \[[@B14]\]. Evaluating adverse pregnancy outcomes to pollutants, drugs, and various exposures based on maternal metabolite profiles seem to be a logical next step. Exposome markers not only give rise to specific phenotypes but also modify the metabolic phenotype depending on the health status of the individual. In addition to external exposome, the endogenous exposome, which are the chemicals generated within the human body in response to external stimuli through various physiological processes (e.g., oxidative stress, inflammation, or infections) should also be investigated \[[@B166]\].

Currently, the major focus in pregnancy-related exposure investigations is on pesticides, tobacco smoke, drug abuse, alcohol dependence, and exposure to mercury \[[@B94], [@B167], [@B168]\]. These pollutants can be transported from mother to fetus through the placenta. Prenatal and neonatal samples such as maternal and infant hair, meconium, maternal blood, and cord blood have been used in studies done on fetal and maternal exposures. Results from these studies show that meconium provides the most sensitive data representing*in utero* fetal exposure, while maternal hair sampling is the most stable for detecting the maternal exposome \[[@B32], [@B169]--[@B171]\].

Fetal exposure to mercury and more specifically methylmercury (a neurotoxin) during pregnancy could occur through maternal consumption of mercury-contaminated fish \[[@B172], [@B173]\]. Fetal exposure to pesticides could occur through contaminated food and water, inhalation of pesticide-polluted air, or skin contact. Some pesticides are also neurotoxic and could result in mental retardation, learning disabilities, autism, attention deficit-hyperactivity disorders, and deficiencies in motor development in the infant \[[@B174], [@B175]\]. Furthermore, increased risks of IUGR, PTB, miscarriage, and fetal alcohol syndrome have been associated with exposure to pollutants during pregnancy \[[@B176]--[@B178]\]. One study by Bonvallot et al. (2013) has demonstrated that 5 metabolites (glycine, threonine, lactate, glycerophosphocholine, and citrate) in the urine were significantly different between pesticide-exposed and unexposed pregnant women \[[@B179]\]. Comprehending the associations between the exposome and adverse pregnancy outcomes and future health of fetus is crucial in risk estimation and prediction of developing pregnancy complications, and further studies into the exposome should be conducted.

6. Conclusion {#sec6}
=============

It is well-established that the first 1000 days of human life, calculated from conception, are crucial in determining well-being throughout the entire lifespan \[[@B180]\]. The most recent research studies have further suggested that maternal health condition even before conception is also involved in determining fetal health \[[@B181]\]. Therefore, the maternal metabolome should be monitored or assessed as early as possible. Given that many pregnancies are unplanned and first blood draw or urine collection is done in the pregnancy clinic, a biological sample that could be collected after conception but able to reveal the preconception metabolome would prove to be extremely valuable. This is one main advantage of using hair as a biological sample. In addition, analysis of the hair metabolome also holds potential for early diagnosis and risk identification biomarkers for various pregnancy complications and harmful exposures during pregnancy. Preventative plans and /or personalized treatment plans could be created from the data obtained from these studies. Other advantages of using hair as a biological sample are that hair sampling is noninvasive and safe for both mother and fetus, and the hair metabolome is stable and can be preserved for months at room temperature without any special preparation. Thus, further studies of the hair metabolome relating to pregnancy complications could open the door to many significant practical advances in the way these conditions are dealt with in the clinical setting.
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###### 

Examples of metabolomics studies associated with preeclampsia (EO-PE: early-onset preeclampsia, LO-EP: late-onset preeclampsia, and PE: preeclampsia).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sample specimen                            Participants (n)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Outcomes                                                                    Analytical platforms              Metabolites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Statistical analysis                                                                                                                                                                   References
  ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Serum                                      80 (20 EO-PE, 20 LO-PE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             EO-PE, LO-PE, controls for both                                             FTIR spectroscopy, H^1^ NMR       FTIR results: carbohydrate, protein and lipid region sign. Different in EO-PE, H^1^ NMR model included: ↑Glutamate, choline, alanine, lactate ↓ arginine, citrate                                                                                                                                                                                                                                                                                                                                                    P\<0.001, 95% CI                                                                                                                                                                       \[[@B40]\]

  Plasma                                     Cohort 1: 40 (20 PE); cohort 2: 174 (87 PE) \[[@B43]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Preeclampsia and controls                                                   UPLC-LTQ Orbitrap-MS              Alanine, 2-Hydroxy-3-methyl-butanoic acid, 2-Ethyl-3-hydroxypropionic acid, 2-Oxoglutaric acid, Glutamic acid, Xylitol or ribitol, Uric acid, Creatinine                                                                                                                                                                                                                                                                                                                                                             P\<0.01                                                                                                                                                                                \[[@B44]\]

  Plasma (15+/- 1 weeks of gestation)        120 (discovery, 60 PE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              PE and controls                                                             UPLC-MS                           Study 1: 45 unique metabolites divided into 11 clear metabolite classes: amino acids, carbohydrates, carnitines, Eicosanoids, fatty acids, keto or hydroxy acids, lipids, phospholipids, porphyrins, phosphatidylserine, and steroids.                                                                                                                                                                                                                                                                               study 1: P\<0.05                                                                                                                                                                       \[[@B45]\]

  79 (validation, 39 PE)                     Study 2: data mining and modeling techniques it gave rise of a model containing 14 metabolites (5-Hydroxytryptophan, Monosaccharide(s), Decanoylcarnitine, Methylglutaric acid and/or adipic acid*∗*, Oleic acid, Docosahexaenoic acid and/or Docosatetraenoic acid, -Butyrolactone and/or oxolan-3-one, 2-Oxovaleric acid and/or oxo-methylbutanoic acid, Acetoacetic acid, Hexadecenoyl- eicosatetraenoyl-sn- glycerol*∗*, Di-(octadecadienoyl)-sn- glycerol*∗*, Sphingosine 1-phosphate, Sphinganine 1-phosphate, Vitamin D3 derivatives) to be a robust model to predict PE with AUC of \>0.9   Study 2: P\<0.05, robust predictive model of 14 metabolites: AUC of \>0.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Placenta (first trimester)                 Study 1: 12 (terminated pregnancy); study 2: 17 (6 PE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Late PE, controls                                                           GC-TOF-MS, UPLC-LTQ Orbitrap-MS   classes which are significantly different between term PE and normal term pregnancies: acyl glycerides, phospholipids, fatty acids and related metabolites, amino acids related metabolites, vitamin D-related metabolites, isoprenoids, and steroids                                                                                                                                                                                                                                                                P\<0.05                                                                                                                                                                                \[[@B46]\]

  Serum (11(+0)-13(+6) weeks of gestation)   119 (30 LO-PE, 30 EO-PE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            LO-PE, EO-PE, controls                                                      NMR                               1st analysis (late onset PE vs controls): 17 metabolites significant different, of which Glycerol, carnitine, methylhistidine, acetone most important to discriminate based on VIP.\                                                                                                                                                                                                                                                                                                                                 P\<0.05, complex model (metabolites/maternal demographic info): 76.6% sensitivity at 100% specificity, simplified model: 60% sensitivity at 96.6% specificity                          \[[@B47]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               2nd analysis (Late onset vs early onset PE): glycerol, acetate, trimethylamine and succinate most important to discriminate based on VIP analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Plasma (11-13 weeks)                       90 (30 EO-PE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       EO-PE, controls                                                             NMR                               Model 1: metabolites (glutamine, pyruvate, propylene glycol, trimethylamine, hydroxybutyrate) in combination with maternal characteristics (weight and medical disorder) and Model 2: metabolites (glutamine, pyruvate, propylene glycol, trimethylamine, hydroxybutyrate, carnitine, hydroxy isovalerate) in combination with uterine artery PI.                                                                                                                                                                    P\<0.005, model 1: estimated detection rate is 75.9%, model 2: estimated detection rate is 82.6%                                                                                       \[[@B48]\]

  Serum (11(+0)-13(+6) weeks of gestation)   Discovery: 95 (30 EO-PE); Validation: 63 (20 EO-PE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 EO-PE, controls                                                             NMR                               Metabolite-only model: glycerol, 3-hydroxyisovalerate, 2-hydroxybutyrate, acetone, and citrate; combined logistic regression model: glycerol, 3-hydroxyisovalerate, arginine, and UtPI data                                                                                                                                                                                                                                                                                                                          Metabolite only model: O.835 of AUC; combined logistic regression model (metabolite plus uterine Doppler pulsatility index): 0.916 of AUC for early PE detection in validation group   \[[@B49]\]

  Serum (11-14 weeks of gestation)           82 (41 PE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          PE and controls                                                             LC-MS/MS                          Hydroxyhexanoylcarnitine, phenylalanine, glutamate, alanine, were significantly higher in PE cases compared to controls and adjusted by BMI, ethnicity and pregestational diabetes,                                                                                                                                                                                                                                                                                                                                  P\<0.05, individual metabolites AUC of 0.77-0.80, combined metabolites AUC of 0.82 for all PE cases and 0.85 for EO-PE cases                                                           \[[@B50]\]

  Urine, Serum at time of diagnosis          30 (10 PE, 10 controls, 10 non-pregnant)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            PE and controls (pregnant and non-pregnant)                                 NMR                               Urine: by PLS-DA: ↑choline and creatinine level, ↓ glycine levels in PE aces vs healthy pregnancies, women with early onset PE had ↑Trimethylamine-N-oxide, creatinine, ↓choline and creatinine compared to late onset PE; Serum: lipid content PE cases\>normal pregnancies\>nonpregnant women. Distribution of lipoproteins was also different between groups with PE cases most ↑ levels from VLDL and LDL and ↓ levels of HDL, PE cases had significantly ↓ levels of histidine compared to healthy pregnancy.   P\<0.05 (PCA) and P\<0.001 (PLS-DA), 95% significance of the predictive model                                                                                                          \[[@B51]\]

  Urine, serum (first trimester)             599 (26 PE, 21 gest. Hypertension)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  PE, gestational hypertension, controls                                      NMR                               ↑ levels of creatinine, glycine, 4-deoxythreonic acid, *α*-hydroxyisobutyrate, histidine and dimethylamine, ↓ levels of hippurate, lactate and proline betaine in the urine of women which developed preeclampsia. Women who developed gestational hypertension had an additional ↓ of citrate level in urine. In serum samples: ↑ lipid levels in both hypertensive groups. ↓ levels of phosphatidylcholines, glucose, lactate, and alanine.                                                                        P\<0.05,Urine: 51.3% sensitivity for PE and 40% gestational hypertension, Serum: 15% sensitivity for PE and 33% gestational hypertension                                               \[[@B52]\]

  Serum(8(+0)-13(+6) weeks of gestation)     667 (68 EO-PE, 99 LO-PE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            EO-PE, LO-PE, controls                                                      UPLC-MS/MS, LC-MS                 EO-PE vs controls: taurine and asparagine; LO-PE vs controls: glycylglycine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 \[[@B41]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Examples of metabolomic studies associated with FGR/SGA.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sample specimen                       Participants (n)        Outcomes                                Analytical platforms   Metabolites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Statistical analysis                                                                   References
  ------------------------------------- ----------------------- --------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ------------
  Cord blood: serum                     43 (22 IUGR)            IUGR, AGA (appropriate for gest. Age)   LC-HRMS (orbitrap)     Phenylalanine, tryptophan, and glutamate to discriminate between IUGR and AGA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    P\<0.05, ROC curve: sensitivity between 91-100% and specificity between 85-89%         \[[@B64]\]

  Fetal rabbit brain tissue             Living: 9 (4IUGR)\      IUGR, control                           LC-QTOF-MS             N-acetylaspartylglutamic acid (NAAG), N-acetylaspartate (NAA), ornithine, L-lysine, asparagine, histidine, and leucine intermediate 2-keto-isovalerate, succinate, pantothenate, malondialdehyde and 3-nitrotyrosine, purine, 3,4-dihydroxybutyric acid, nucleotide GMP, docosahexaenoic acid (DHA), palmitoleic acid and oleic acid                                                                                                                                                                                                                                                                             P\<0.05                                                                                \[[@B56]\]
                                        Stillborn: 7 (6 IUGR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Urine (end of the first trimester)    464 (36 FGR, 19 SGA)    FGR, SGA, Controls                      NMR                    significant association FGR with decreased levels of acetate, formate, tyrosine and trimethylamine in urine adjusted for education, maternal age, parity, smoking during pregnancy; SGA was associated with leucine and N-acetyl neuraminic acid                                                                                                                                                                                                                                                                                                                                                                 95% confi.int., AUC for FGR: 63.7-66.3%                                                \[[@B55]\]

  Urine of IUGR newborns                56 (26 IUGR)            IUGR, controls                          NMR                    Discrimination between IUGR and control neonates by myo-inositol, sarcosine, creatine and creatinine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             /                                                                                      \[[@B65]\]

  \(a\) cord plasma\                    \(a\) 14 (8 SGA)\       SGA, control                            UPLC-MS                Pregnanediol-3-glucuronide OR 3alpha,20alpha-dihydroxy-5beta-pregnane 3-glucuronide, LysoPC(16:1) OR Cervonyl carnitine,6-hydroxysphingosine OR (4OH,8Z,t18:1) OR 3b-Allotetrahydrocortisol OR 15-methyl-15-PGD2 OR 15R-PGE2 methyl ester, Leucyl-leucyl-norleucine OR Sphingosine 1-phosphate, Cervonyl carnitine AND/OR 1R,25-dihydroxy-18-oxocholecalciferol, 17-\[(Benzylamino)methyl\]estra-1,3,5(10)-triene-3,17beta-diol, PC, phosphocholine; PGD, Prostaglandin D; PGE, prostaglandin E. significant different between SGA and controls in both studies associated with cord plasma and week 15 plasma   P\<0.05, robust predictive model of 19 metabolites of presymptomatic SGA: AUC of 0.9   \[[@B57]\]
  (b) early pregnancy maternal plasma   (b) 340 (73 SGA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Examples of metabolomics studies associated with preterm birth.

  Sample specimen                      Participants (n)                 Outcomes                                           Analytical platforms   Metabolites                                                                                                                                                                         Statistical analysis                                                                                                                                                                                                                              References
  ------------------------------------ -------------------------------- -------------------------------------------------- ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Urine (end of the first trimester)   464 (88 spont. PB, 26 ind. PB)   Preterm birth (spontaneous and induced), control   NMR                    Spontaneous PB associated with increased urine lysine, clinically induced PB was associated with in overweight and obese women and increased resonance in a N-acetyl glycoprotein   95% confi.int., AUC for SPB: 58.8-59.4%, for IPB: 66%                                                                                                                                                                                             \[[@B55]\]
  Cervicovaginal fluid                 219                              Preterm birth, controls                            NMR                    Higher lactate level in term ALR group compared to term and preterm AHR women, acetate was increased in preterm compared to the term group for SYM and AHR group                    P\<0.05, acetate integrals in PTB versus term for AHR and SYM group: predictive of preterm birth \<37 gestational weeks is AUC of 0.78, acetate integrals in PTB versus term Sym group: delivery within 2 weeks of index assessment AUC of 0.84   \[[@B68]\]
  Cervicovaginal secretions            15 (5 Spont. PB)                 Preterm birth, control                             UPLC-QTOF-MS           17 markers were observed to distinguish between preterm birth and control groups; further research is needed                                                                        P\<0.05                                                                                                                                                                                                                                           \[[@B67]\]

###### 

Examples of metabolomic studies associated with gestational diabetes mellitus.

  Sample specimen                                                     Participants (n)   Outcomes                       Analytical platforms                                                                                                                                             Metabolites                                                                                                                                                                                                                                                                                                                                            Statistical analysis                                                                                                                                                                                 References
  ------------------------------------------------------------------- ------------------ ------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Plasma                                                              31 (18 GDM)        GDM vs controls                LC-ESI-QqQ-MS/MS                                                                                                                                                 L-asparagine (Asn), L-valine (Val), and L-ornithine (Orn) were decreased and L-citrulline (Cit) was elevated in GDM cases compared to controls                                                                                                                                                                                                         P\<0.05                                                                                                                                                                                              \[[@B86]\]
  Serum (3rd trimester)                                               22 (12 GDM)        GDM vs controls                UPLC-QTOF-MS                                                                                                                                                     9 metabolites were observed with AUC\>0.7 to diagnose GDM from healthy controls which are 1- methyladenosine, glucosamine, L-tyrosine, phosphorylcholine, L-lactic acid, 3-methylthiopropionic acid, lysoPC(16:1), L-2- hydroxyglutaric acid, and trans-3-octenedioic acid                                                                             P\<0.05                                                                                                                                                                                              \[[@B75]\]
  Serum (16 weeks of gestation)                                       358 (178 GDM)      GDM vs controls                GC-MS                                                                                                                                                            17 metabolites: linoleic acid, oleic acid, myristic acid, d-galactose, d-sorbitol, o-phosphoco- lamine, l-alanine, l-valine, 5-hydroxy-l-tryptophan, l-phenylalanine-phenyl, l-serine, sarcosine, l-pyroglutamic acid, and l-mimosine, l-lactic acid, glycolic acid, fumaric acid, and urea expressed differentiation between GDM cases and controls   Regression analysis, these metabolites together with GDM risk factors (maternal age, family history, prepregnancy BMI, ferritin, CRP, hep- cidin, and total vitamin D) gave rise to an AUC of 0.87   \[[@B87]\]
  Plasma (24-27 weeks of gestation, at OGTT test)                     24 (9 GDM)         GDM vs controls at OGTT test   FIA-MS/MS and LC-MS for amino acids, acylcarnitines, sphingomyelins, phosphatidylcholines, hexose (glucose) and biogenic amines; Fatty acids analysis by GC-MS   reference model complemented by a clinical model(BMI, AUC of glucose and insulin) gave rise to 8 metabolites C18:0 carnitine, PC aa C34:4, PC aa C36:4, PC aa C38:5, PC ae C36:4, PC ae C36:5, LPC C20:4 and arachidonic acid which showed differences between GDM cases and controls                                                                  P\<0.01, reference model: 96.4% AUC and clinical model: 99.3% AUC                                                                                                                                    \[[@B74]\]
  Serum (fasting)                                                     192 (96 GDM)       GDM vs controls                LC-MS                                                                                                                                                            anthranilic acid, alanine, glutamate, allantoin and serine were increased and creatinine decreased in GDM cases compared to controls                                                                                                                                                                                                                   P\<0.05                                                                                                                                                                                              \[[@B88]\]
  Serum (20 weeks)                                                    48 (22 GDM)        GDM vs controls                GC-MS                                                                                                                                                            Itaconic acid with P=0.0003 was significantly increased in women who developed GDM later on during pregnancy compared to controls, cis-aconitate levels were also higher in GDM cases and verging on statistical difference (P=0.013)                                                                                                                  P\<0.01                                                                                                                                                                                              \[[@B85]\]
  Urine and plasma (Fasting)                                          40 (20 GDM)        GDM vs controls                LC-QTOF-MS(plasma), GC-Q/MS(plasma), CE-TOF/MS(urine)                                                                                                            After ROC analysis metabolites with a ROC area \>0.94 and has shown a discriminative ability by 25 lysoglycerophospholipids, arachidonic 20:4) and docosahexaenoic (22:6) acid methyl esters, and taurine-conjugated bile acids. Lipoxin was another lipid which showed a high discriminative power and associated with diabetic outcome               ROC area\>0.94                                                                                                                                                                                       \[[@B76]\]
  Urine (8-20 gest. week, week 28+/-2, 10-16 weeks after pregnancy)   609 (13% GDM)      GDM vs controls                NMR                                                                                                                                                              Significant increase of citrate levels associated with GDM severity                                                                                                                                                                                                                                                                                    P\<0.05, R2\>95%                                                                                                                                                                                     \[[@B89]\]

###### 

Consensus on alcohol markers in hair analysis by Society of Hair Testing.

                Total Abstinence   Chronic Excessive Consumption        Hair segment
  ------------- ------------------ ------------------------------------ ----------------------------------------
  EtG           \<7 pg/mg          ≥30 pg/mg                            proximal scalp hair segment up to 6 cm
  FAEEs         \<0.12ng/mg        ≥0.35 ng/mg                          0-3 cm proximal scalp hair segment
  \<0.15ng/mg   ≥0.45 ng/mg        0-6 cm proximal scalp hair segment   

###### 

Examples of hair metabolomic studies associated with complicated pregnancies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sample specimen   Participants (n)         Outcomes          Analytical platforms   Metabolites                                                                         Statistical analysis   References
  ----------------- ------------------------ ----------------- ---------------------- ----------------------------------------------------------------------------------- ---------------------- -------------
  Maternal hair     83(41 FGR,42 Controls)   FGR vs Controls   GC-MS                  5 discriminating metabolites (lactate, levulinate, 2-methyloctadecanate,\           P\<0.01                \[[@B160]\]
                                                                                      tyrosine, and margarate) were observer between FGR and normal pregnancies                                  

  Maternal hair     94(47 GDM,47 Controls)   GDM vs controls   GC-MS                  adipic acid significantly elevated in GDM compared to the control group (P=0.002)   P\<0.05                \[[@B161]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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